Quote of the Day: Earth Is Being Cooked at a Quickening Pace
KATE MARVEL, a climate scientist, noting that more people will experience climate change in damaging and frightening ways as the world continues to emit planet-warming greenhouse gases.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Electrophysiology Market worth US$21.72 billion by 2030 with 11.6% CAGR
DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Electrophysiology Market, valued at US$11.41 billion in 2024, stood at US$12.55 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2025 to 2030, culminating in a forecasted valuation of US$21.72 billion by the end of the period. The rise of the electrophysiology market can be attributed to several drivers: the increasing prevalence of cardiovascular diseases, including arrhythmias and atrial fibrillation; patients and healthcare providers are increasingly favoring minimally invasive procedures over traditional surgical interventions; electrophysiological techniques, such as catheter ablation, offer less invasive options for treating certain cardiac arrhythmias; and government support and initiatives aimed at improving healthcare infrastructure and funding research and development in electrophysiology also contribute to market growth. Download PDF Brochure: Browse in-depth TOC on "Electrophysiology Market" 322 - Tables62 - Figures330 - Pages By product, in 2024, electrophysiology ablation catheters are expected to be the leading segment in the medical device market. This anticipated growth is largely driven by the rising global prevalence of atrial fibrillation (AF) and various cardiac arrhythmias, which has increased the demand for minimally invasive ablation techniques. Recent technological advancements in catheter design, such as the introduction of contact force-sensing mechanisms, irrigated-tip designs, and high-power short-duration (HPSD) ablation systems, have greatly enhanced procedural safety, precision, and clinical outcomes. These innovations are contributing to wider acceptance and increased utilization of these catheters within the medical community. By indication, the electrophysiology market, divided by medical indications, includes segments such as atrial fibrillation, atrial flutter, and atrioventricular nodal reentry tachycardia. Atrial flutter, characterized by rapid heartbeats from the atria, is increasingly common, especially among the elderly, due to age-related cardiac changes. This rising prevalence has created a demand for advanced diagnosis and treatment options tailored to atrial flutter. Innovations in catheter ablation, advanced imaging techniques, and new pharmacological therapies reflect the urgency for effective arrhythmia management in an aging population. By geography, in 2024, North America, primarily the US and Canada, is set for significant growth in the medical technology market. The region is a global leader in medical innovations, especially in electrophysiology, often adopting breakthroughs ahead of others. With some of the highest healthcare spending globally, the US influences the uptake of advanced medical technologies, enhancing patient outcomes and operational efficiency. Strong A investment in research and development fosters innovation and creates a robust marketplace for new products and services, solidifying North America's role as a key driver of growth in the medical technology sector. Request Sample Pages : As of 2024, prominent players in the electrophysiology market are Johnson & Johnson Services, Inc. (US), Abbott (US), Medtronic (Ireland), Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), Boston Scientific Corporation (US), Japan Lifeline Co., Ltd (Japan), Stereotaxis, Inc. (US), MicroPort Scientific Corporation (China), and BIOTRONIK (Germany). Abbott (US): Abbott Laboratories is a comprehensive healthcare company that operates across diverse sectors, including pharmaceuticals, medical devices, diagnostics, and nutrition. The company has established a significant presence in electrophysiology, particularly in the development of advanced medical devices for cardiac electrophysiology procedures. Abbott's portfolio in this specialized market includes sophisticated mapping systems, electrophysiology catheters, and related technologies designed for the precise diagnosis and management of cardiac arrhythmias. Furthermore, Abbott is likely engaged in ongoing research and development initiatives aimed at innovating and enhancing electrophysiological technologies to improve patient outcomes and procedural efficiencies. Koninklijke Philips N.V. (Netherlands) Koninklijke Philips N.V. Philips, a Netherlands-based multinational company, is a significant player in the healthcare sector, particularly within medical technology. The company develops an extensive range of products that enhance capabilities in cardiology, patient monitoring, diagnostic imaging, and electrophysiology. In the electrophysiology domain, Philips offers advanced solutions aimed at the identification and management of cardiac arrhythmias. This product suite includes high-precision imaging technologies, advanced mapping systems, and specialized electrophysiology catheters, all essential tools utilized by cardiology professionals. Key offerings include the EP WorkMate system, which serves as a comprehensive electrophysiology recording and reporting platform, facilitating efficient data capture and analysis during procedures. Additionally, Philips has introduced state-of-the-art X-ray imaging systems designed for enhanced visualization during electrophysiological interventions. The EP Navigator and EP-XT Mapping system are also part of their innovative portfolio, providing clinicians with advanced three-dimensional mapping capabilities that improve procedural accuracy and patient outcomes. For more information, Inquire Now! Related Reports: Defibrillator Market Cardiac Monitoring & Cardiac Rhythm Management Devices Market Ablation Technology Market Catheters Market Digital X-ray Market Get access to the latest updates on Electrophysiology Companies and Electrophysiology Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets
Yahoo
12 minutes ago
- Yahoo
A 19-Year-Old Chemist Turned a Perfume Ingredient Into a Lifesaving Drug
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Here's what you'll learn when you read this story: 19-year-old Adam Kovalčík has created a stronger—and much cheaper—version of a powerful emerging medication known as galidesivir. Instead of starting out with the sugar, which is normally used in the production of this drug, he rebuilt the formula with a base molecule of corn alcohol. This change increases efficiency and cuts costs by reducing production steps and using inexpensive materials. We live in the aftermath of a global pandemic. Leftover COVID-19 trauma and world news updates reporting outbreaks of Zika or Ebola have made us apprehensive about viruses, and most of us have been vigilant about being vaccinated and re-vaccinated. But what about when preventative measures aren't enough? What happens if a virus invades us before we can get to a vaccine? Adam Kovalčík is only 19, but the high school senior at Gymnázium Nové Zámky in Slovakia he has created something beyond what anyone would expect of someone his age. He has managed to turn an alcohol derived from corncobs and husks into galidesivir, an antiviral drug that targets RNA viruses like Zika and Ebola. Generating the drug this way, in his words, 'could potentially save tens of thousands of lives.' Kovalčík recently won the $100,000 Genrge D. Yancopoulos Innovator Award at the 2025 Regeneration International Science and Engineering Fair (ISEF). Galidesivir is the human-synthesized version of adenosine, which itself is a nucleoside—the components of nuclei acids. Among other biochemical functions, they are involved in storing and transferring genetic information. Adenosine is also an inhibitor of the enzyme RNA polymerase, which interferes with the function of certain enzymes in RNA viruses. The adenosine produced by our our bodies can inhibit RNA viruses (which clone their genomes in order to keep producing infinite copies of themselves), but it usually needs a boost when faced with potentially fatal pathogens like Ebola and Zika. This is where galidesivir comes in. Though not yet approved by the FDA, in vitro and animal tests have shown that galidesivir increases survival rates and has few side effects, which is why it is also being considered for treating COVID-19. It binds to the molecules that viruses use to clone themselves, making that function no longer accessible to the virus. The problem with galidesivir is that it costs $75 per gram (0.035 ounce) to produce, making the cost of a future prescription almost unfathomable, especially considering the state of healthcare. Kovalčík's process could bring that cost down to $12.50 per gram. Why is galidesivir so expensive? There is an extra step in the production of the most powerful form of this drug that ultimately affects the cost. When drugs are being developed, unwanted materials—such as variants of that drug—often end up in the first batch. These variants, or stereoisomers, have the same molecular formula as the finished drug, but their atoms form molecules in different arrangements. Kovalčík wanted to synthesize cis-OH galidesivir because it is 20 times stronger than its stereoisomer trans-OH galidesivir, so the trans version needs to be separated out to isolate the cis version. Separation involves extras steps that take extra time and cost more. Kovalčík used his experience working on perfumes in a chemistry lab to figure out how to synthesize galidesivir in a different way. He needed a starter molecule—typically, sugar is used for galidesivir, but sugar would just repeat the existing process, which was not efficient enough. Perfume taught Kovalčík that some scent compounds used furfural alcohol (corn alcohol) as a starter molecule, so he rebuilt the drug using it as the replacement starter molecule and was able to reduce the production steps from 15 to 10. Using corn alcohol also lowered the cost. This production method is not restricted to galidevisir—it could create other antivirals. Kovalčík used computer models to design new molecules that were supposed to operate in the same way as galidesivir, and one molecule he came up with (ADK-98) had the potential to be even more effective. The furfural alcohol distilled from corn would be the base for these future drugs. Kovalčík plans to continue refining his research and development process for this and other potential antivirals in collaboration with the Slovak University of Technology in Bratislava. And to think, this all started with a realization that came from molecules in perfume. Think about that with your next spritz of Dior Homme or Chanel No. 5. You Might Also Like The Do's and Don'ts of Using Painter's Tape The Best Portable BBQ Grills for Cooking Anywhere Can a Smart Watch Prolong Your Life? Solve the daily Crossword
Yahoo
36 minutes ago
- Yahoo
JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025
Register for the three-day event here FRENCHTOWN, NJ / / August 15, 2025 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced its companies will present at the Webull Corporate Connect Webinar Series: Biotech/MedTech being held virtually on August 19-21, 2025. The event will feature three days of presentations from participating companies and interactive Q&A sessions. The schedule of presenting companies is: Tuesday, August 19th 2:00 PM ET: Akari Therapeutics, Plc (NASDAQ:AKTX) 2:20 PM ET: Senti Biosciences, Inc. (NASDAQ:SNTI) 2:40 PM ET: CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Wednesday, August 20th 2:00 PM ET: Moleculin Biotech, Inc. (NASDAQ:MBRX) 2:20 PM ET: GRI Bio, Inc. (NASDAQ:GRI) 2:40 PM ET: AIM ImmunoTech, Inc. (NYSE American:AIM) Thursday, August 21st 2:00 PM ET: enVVeno Medical Corporation (NASDAQ:NVNO) 2:20 PM ET: Autonomix Medical, Inc. (NASDAQ:AMIX) 2:40 PM ET: Nuwellis, Inc. (NASDAQ:NUWE) All investors and interested parties can register for the event and access the schedule of participating companies here. JTC Team is a paid consultant to the participating companies. JTC Team is an investor relations and corporate communications firm. Any content included in this release shall not be construed as an offer to purchase securities of the applicable companies. Interested parties are responsible for conducting their own due diligence and are encouraged to review the companies' websites and the SEC website for the latest information and filings on each company. About JTC Team JTC is a fully integrated investor relations firm that is dedicated to helping you tell your story to the right audiences in order to build awareness. JTC has developed a reputation of excellence for executing on robust communication strategies that deliver results. The Company partners with both public and private companies across the Life Sciences and Technology industries to help raise awareness and build stakeholder value. For more information, please visit or connect with the company on X and LinkedIn. Contact: Jenene ThomasJTC Team, LLCT: +1 (908) 824-0775jtc@ SOURCE: JTC Team, LLC View the original press release on ACCESS Newswire
